| 1 | Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database | 2.9 | 4 | Citations (PDF) |
| 2 | Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer | 2.9 | 17 | Citations (PDF) |
| 3 | ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer | 14.2 | 75 | Citations (PDF) |
| 4 | Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology | 5.2 | 5 | Citations (PDF) |
| 5 | Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials | 3.2 | 4 | Citations (PDF) |
| 6 | Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors | 3.2 | 64 | Citations (PDF) |
| 7 | Landscape of <i>KRAS</i><sup>G12C</sup>, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i>-Mutated Cancers | 3.2 | 67 | Citations (PDF) |
| 8 | Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer | 6.4 | 52 | Citations (PDF) |
| 9 | Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer | 3.3 | 11 | Citations (PDF) |
| 10 | Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis | 3.8 | 3 | Citations (PDF) |
| 11 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials | 14.2 | 153 | Citations (PDF) |
| 12 | Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial | 3.6 | 8 | Citations (PDF) |
| 13 | Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group | 3.6 | 8 | Citations (PDF) |
| 14 | Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer | 7.3 | 107 | Citations (PDF) |
| 15 | Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial | 11.2 | 348 | Citations (PDF) |
| 16 | Clinical and Functional Characterization of Atypical<i>KRAS</i>/<i>NRAS</i>Mutations in Metastatic Colorectal Cancer | 6.4 | 36 | Citations (PDF) |
| 17 | Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers | 0.2 | 3 | Citations (PDF) |
| 18 | Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types | 1.9 | 11 | Citations (PDF) |
| 19 | Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer | 3.4 | 19 | Citations (PDF) |
| 20 | Microsatellite Stable Colorectal Liver Metastases—Understanding the Mechanisms of Immune Resistance | 6.6 | 6 | Citations (PDF) |
| 21 | Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting | 1.3 | 1 | Citations (PDF) |
| 22 | BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer | 2.0 | 37 | Citations (PDF) |
| 23 | Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines | 12.1 | 151 | Citations (PDF) |
| 24 | Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients | 7.0 | 13 | Citations (PDF) |
| 25 | Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study | 2.7 | 20 | Citations (PDF) |
| 26 | Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer | 3.6 | 41 | Citations (PDF) |
| 27 | Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials | 1.3 | 5 | Citations (PDF) |
| 28 | Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer | 0.6 | 22 | Citations (PDF) |
| 29 | A new prognostic and predictive tool for shared decision making in stage III colon cancer | 2.9 | 54 | Citations (PDF) |
| 30 | Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma | 2.7 | 43 | Citations (PDF) |
| 31 | Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials | 11.2 | 223 | Citations (PDF) |
| 32 | Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care | 25.1 | 34 | Citations (PDF) |
| 33 | Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction? | 8.6 | 13 | Citations (PDF) |
| 34 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study | 14.8 | 1,541 | Citations (PDF) |
| 35 | WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype | 4.1 | 20 | Citations (PDF) |
| 36 | Evolution of Cancer Care in Response to the COVID-19 Pandemic | 3.6 | 9 | Citations (PDF) |
| 37 | Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance) | 3.8 | 19 | Citations (PDF) |
| 38 | A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group | 3.6 | 567 | Citations (PDF) |
| 39 | Molecular profile of BRCA-mutated biliary tract cancers | 2.7 | 86 | Citations (PDF) |
| 40 | Evolving role of regorafenib for the treatment of advanced cancers | 10.0 | 89 | Citations (PDF) |
| 41 | EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit? | 11.2 | 11 | Citations (PDF) |
| 42 | Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer | 1.7 | 18 | Citations (PDF) |
| 43 | Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors | 4.5 | 150 | Citations (PDF) |
| 44 | Personalizing Treatment for Rectal Cancer | 6.6 | 5 | Citations (PDF) |
| 45 | Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study | 11.2 | 239 | Citations (PDF) |
| 46 | Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer | 25.1 | 1,282 | Citations (PDF) |
| 47 | Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer | 1.8 | 5 | Citations (PDF) |
| 48 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials | 8.6 | 736 | Citations (PDF) |
| 49 | Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study | 14.2 | 216 | Citations (PDF) |
| 50 | Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine | 2.5 | 10 | Citations (PDF) |
| 51 | Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study | 2.7 | 50 | Citations (PDF) |
| 52 | Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study | 3.6 | 112 | Citations (PDF) |
| 53 | Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers | 3.4 | 31 | Citations (PDF) |
| 54 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine | 2.7 | 39 | Citations (PDF) |
| 55 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers | 2.9 | 198 | Citations (PDF) |
| 56 | Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience | 3.6 | 45 | Citations (PDF) |
| 57 | MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach | 2.4 | 34 | Citations (PDF) |
| 58 | NCCN Guidelines Insights: Colon Cancer, Version 2.2018 | 10.5 | 825 | Citations (PDF) |
| 59 | A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience | 3.6 | 20 | Citations (PDF) |
| 60 | Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set | 2.7 | 18 | Citations (PDF) |
| 61 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer | 25.1 | 896 | Citations (PDF) |
| 62 | Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance) | 1.1 | 15 | Citations (PDF) |
| 63 | Impact of Metastasectomy in the Multimodality Approach for <i>BRAF</i> V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience | 3.6 | 35 | Citations (PDF) |
| 64 | Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience | 2.7 | 13 | Citations (PDF) |
| 65 | A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer | 6.4 | 22 | Citations (PDF) |
| 66 | Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | 5.8 | 20 | Citations (PDF) |
| 67 | Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database | 2.9 | 14 | Citations (PDF) |
| 68 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer | 2.3 | 23 | Citations (PDF) |
| 69 | Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients | 9.1 | 58 | Citations (PDF) |
| 70 | Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer | 10.5 | 21 | Citations (PDF) |
| 71 | Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group | 2.9 | 33 | Citations (PDF) |
| 72 | 5-fluorouracil and cardiotoxicity: a review | 3.8 | 354 | Citations (PDF) |
| 73 | Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology | 10.5 | 117 | Citations (PDF) |
| 74 | Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology | 10.5 | 810 | Citations (PDF) |
| 75 | Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance) | 0.2 | 0 | Citations (PDF) |
| 76 | European Society for Medical Oncology Copenhagen update: potential practice-changing findings | 3.8 | 0 | Citations (PDF) |
| 77 | Napabucasin: An Update on the First-in-Class Cancer Stemness InhibitorDrugs, 2017, 77, 1091-1103 | 9.1 | 146 | Citations (PDF) |
| 78 | Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology | 10.5 | 773 | Citations (PDF) |
| 79 | Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) | 4.7 | 7 | Citations (PDF) |
| 80 | Evidence in Favor of Standard Surgical Treatment for Rectal Cancer | 8.6 | 5 | Citations (PDF) |
| 81 | Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers | 11.2 | 3 | Citations (PDF) |
| 82 | Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer | 2.7 | 43 | Citations (PDF) |
| 83 | Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies | 3.8 | 42 | Citations (PDF) |
| 84 | Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment | 1.9 | 21 | Citations (PDF) |
| 85 | <sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer | 14.2 | 314 | Citations (PDF) |
| 86 | Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database | 14.2 | 45 | Citations (PDF) |
| 87 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 | 2.7 | 97 | Citations (PDF) |
| 88 | Colorectal cancer: how to teach an old drug new tricks | 40.1 | 1 | Citations (PDF) |
| 89 | Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254 | 11.2 | 106 | Citations (PDF) |
| 90 | Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study | 3.0 | 62 | Citations (PDF) |
| 91 | Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer | 3.6 | 40 | Citations (PDF) |
| 92 | Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505) | 2.5 | 79 | Citations (PDF) |
| 93 | Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) | 3.6 | 42 | Citations (PDF) |
| 94 | Adverse event development in clinical oncology trials – Authors' reply | 11.2 | 1 | Citations (PDF) |
| 95 | Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database | 11.2 | 583 | Citations (PDF) |
| 96 | Adjuvant Therapy for Colon Cancer | 8.6 | 9 | Citations (PDF) |
| 97 | Regorafenib in the treatment of colorectal cancer | 2.3 | 16 | Citations (PDF) |
| 98 | Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database | 14.2 | 36 | Citations (PDF) |
| 99 | Rectal Cancer, Version 2.2015 | 10.5 | 198 | Citations (PDF) |
| 100 | Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer | 10.5 | 2 | Citations (PDF) |
| 101 | Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice | 10.5 | 11 | Citations (PDF) |
| 102 | Molecular profiling in the treatment of colorectal cancer: focus on regorafenib | 1.6 | 8 | Citations (PDF) |
| 103 | Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer | 0.5 | 5 | Citations (PDF) |
| 104 | Rationale for metronomic chemotherapy in phase III trials | 70.2 | 25 | Citations (PDF) |
| 105 | The role of regorafenib in metastatic colorectal cancer | 11.2 | 7 | Citations (PDF) |
| 106 | Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival | 5.2 | 24 | Citations (PDF) |
| 107 | Is obesity an advantage in patients with colorectal cancer? | 2.4 | 25 | Citations (PDF) |
| 108 | The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials | 5.2 | 77 | Citations (PDF) |
| 109 | Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | 11.2 | 314 | Citations (PDF) |
| 110 | Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer | 10.0 | 52 | Citations (PDF) |
| 111 | When less is more: maintenance therapy in colorectal cancer | 14.8 | 13 | Citations (PDF) |
| 112 | Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers | 2.4 | 14 | Citations (PDF) |
| 113 | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study | 11.2 | 875 | Citations (PDF) |
| 114 | Distinctive Tumor Biology of MSI-High Colorectal Cancer | 0.2 | 1 | Citations (PDF) |
| 115 | Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance) | 14.2 | 270 | Citations (PDF) |
| 116 | New Adjuvant Trial Designs in Colon Cancer | 0.2 | 2 | Citations (PDF) |
| 117 | Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database | 14.2 | 91 | Citations (PDF) |
| 118 | Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies | 2.6 | 2 | Citations (PDF) |
| 119 | MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy | 2.5 | 53 | Citations (PDF) |
| 120 | Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients | 0.1 | 11 | Citations (PDF) |
| 121 | Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland | 0.2 | 6 | Citations (PDF) |
| 122 | The search for treatments to reduce chemotherapy-induced peripheral neuropathy | 9.1 | 18 | Citations (PDF) |
| 123 | Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care | 3.6 | 68 | Citations (PDF) |
| 124 | ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer | 5.2 | 71 | Citations (PDF) |
| 125 | Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 | 2.7 | 42 | Citations (PDF) |
| 126 | Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study | 2.1 | 49 | Citations (PDF) |
| 127 | Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 | 5.2 | 154 | Citations (PDF) |
| 128 | The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer | 5.2 | 1 | Citations (PDF) |
| 129 | Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance) | 14.2 | 205 | Citations (PDF) |
| 130 | Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse | 14.2 | 43 | Citations (PDF) |
| 131 | Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations | 2.6 | 106 | Citations (PDF) |
| 132 | Drug rechallenge and treatment beyond progression—implications for drug resistance | 70.2 | 262 | Citations (PDF) |
| 133 | A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial | 1.1 | 262 | Citations (PDF) |
| 134 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | 14.8 | 2,643 | Citations (PDF) |
| 135 | The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status | 0.2 | 101 | Citations (PDF) |
| 136 | Regorafenib for metastatic colorectal cancer – Authors' reply | 14.8 | 9 | Citations (PDF) |
| 137 | VEGF inhibition beyond tumour progression | 11.2 | 9 | Citations (PDF) |
| 138 | Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement | 0.3 | 4 | Citations (PDF) |
| 139 | Phase III Randomized, Placebo(Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1 | 1.2 | 4 | Citations (PDF) |
| 140 | Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database | 14.2 | 71 | Citations (PDF) |
| 141 | Adolescent and Young Adult Colorectal Cancer | 10.5 | 51 | Citations (PDF) |
| 142 | Clinical Trial Designs for Prospective Validation of Biomarkers | 1.3 | 38 | Citations (PDF) |
| 143 | Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer | 7.3 | 432 | Citations (PDF) |
| 144 | Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications | 3.6 | 33 | Citations (PDF) |
| 145 | Reply to M. Mandalà et al | 14.2 | 0 | Citations (PDF) |
| 146 | Reply to S.A. Kesikli et al | 14.2 | 1 | Citations (PDF) |
| 147 | Antiangiogenesis therapy in the treatment of metastatic colorectal cancer | 3.8 | 26 | Citations (PDF) |
| 148 | Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas | 6.4 | 137 | Citations (PDF) |
| 149 | Establishing a Standard of Care for Small Bowel Adenocarcinomas: Challenges and Lessons Learned | 3.6 | 0 | Citations (PDF) |
| 150 | A FACTOR FOUND IN THE IGG FRACTION OF SERUM OF PATIENTS WITH PARANEOPLASTIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION CAUSES PROLIFERATION OF CULTURED HUMAN MELANOCYTES | 1.7 | 80 | Citations (PDF) |
| 151 | Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study | 3.6 | 94 | Citations (PDF) |
| 152 | Treatment options for advanced pancreatic cancer: a review | 2.7 | 37 | Citations (PDF) |
| 153 | S-1 in colorectal cancer: a new standard of care? | 11.2 | 0 | Citations (PDF) |
| 154 | O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) | 1.2 | 1 | Citations (PDF) |
| 155 | Exploring racial differences in outcome and treatment for metastatic colorectal cancer | 4.3 | 38 | Citations (PDF) |
| 156 | Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability–High Colorectal Cancer | 0.2 | 0 | Citations (PDF) |
| 157 | Integrating biomarkers in clinical trials | 2.8 | 137 | Citations (PDF) |
| 158 | Should Oncologists Routinely Discuss Fertility Preservation With Cancer Patients of Childbearing Age? | 2.5 | 6 | Citations (PDF) |
| 159 | Recent developments in therapy for gastrointestinal cancers | 0.1 | 0 | Citations (PDF) |
| 160 | Adjuvant Hepatic Arterial Infusional Chemotherapy | 5.0 | 0 | Citations (PDF) |
| 161 | Reduced Chemotherapy Duration: A Good Idea? | 0.2 | 0 | Citations (PDF) |
| 162 | Curable Metastatic Colorectal Cancer | 4.5 | 45 | Citations (PDF) |
| 163 | Prognostic web‐based models for stage II and III colon cancer | 4.3 | 26 | Citations (PDF) |
| 164 | Reply to A. Chan et al | 14.2 | 0 | Citations (PDF) |
| 165 | Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741 | 3.6 | 16 | Citations (PDF) |
| 166 | <i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice | 3.6 | 16 | Citations (PDF) |
| 167 | Does Stage II Colorectal Cancer Need to Be Redefined? | 6.4 | 7 | Citations (PDF) |
| 168 | Reply to S.B. Park et al | 14.2 | 0 | Citations (PDF) |
| 169 | Antiangiogenesis agents in colorectal cancer | 2.3 | 29 | Citations (PDF) |
| 170 | The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases | 1.9 | 7 | Citations (PDF) |
| 171 | Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future | 1.7 | 5 | Citations (PDF) |
| 172 | Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741 | 14.2 | 205 | Citations (PDF) |
| 173 | Strategies for Managing Chemotherapy-Induced Sensory Neuropathy | 0.2 | 0 | Citations (PDF) |
| 174 | Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators | 2.0 | 22 | Citations (PDF) |
| 175 | Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials | 14.2 | 100 | Citations (PDF) |
| 176 | Reply to D.J. Stewart | 14.2 | 3 | Citations (PDF) |
| 177 | Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set | 14.2 | 75 | Citations (PDF) |
| 178 | Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer | 14.2 | 1,495 | Citations (PDF) |
| 179 | Biomarkers and surrogate end points—the challenge of statistical validation | 70.2 | 297 | Citations (PDF) |
| 180 | Randomized Phase II Trials: Inevitable or Inadvisable? | 14.2 | 79 | Citations (PDF) |
| 181 | Review: Medical treatment of advanced colorectal cancer in 2009 | 3.8 | 7 | Citations (PDF) |
| 182 | Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer | 14.2 | 172 | Citations (PDF) |
| 183 | Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy | 14.2 | 1,240 | Citations (PDF) |
| 184 | Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials | 14.2 | 610 | Citations (PDF) |
| 185 | Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer | 6.4 | 45 | Citations (PDF) |
| 186 | Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study | 3.6 | 298 | Citations (PDF) |
| 187 | In Reply | 14.2 | 0 | Citations (PDF) |
| 188 | Reply to F. Montagnani et al | 14.2 | 0 | Citations (PDF) |
| 189 | Targeting angiogenesis: progress with anti-VEGF treatment with large molecules | 70.2 | 343 | Citations (PDF) |
| 190 | Should bevacizumab be continued beyond progression in colorectal cancer? | 0.2 | 0 | Citations (PDF) |
| 191 | North Central Cancer Treatment Group—Achievements and Perspectives | 2.0 | 6 | Citations (PDF) |
| 192 | Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer | 2.7 | 30 | Citations (PDF) |
| 193 | Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) | 14.2 | 664 | Citations (PDF) |
| 194 | Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107 | 14.2 | 175 | Citations (PDF) |
| 195 | Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer | 9.1 | 47 | Citations (PDF) |
| 196 | Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective | 1.8 | 8 | Citations (PDF) |
| 197 | Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies | 1.9 | 69 | Citations (PDF) |
| 198 | In Reply | 14.2 | 21 | Citations (PDF) |
| 199 | Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab | 2.0 | 34 | Citations (PDF) |
| 200 | A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer | 5.3 | 6 | Citations (PDF) |
| 201 | The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer | 3.6 | 225 | Citations (PDF) |
| 202 | Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate? | 6.4 | 6 | Citations (PDF) |
| 203 | In Reply | 14.2 | 1 | Citations (PDF) |
| 204 | New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer: Summary Statement from 2007 Santa Monica Conference | 6.4 | 15 | Citations (PDF) |
| 205 | Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials | 14.2 | 2 | Citations (PDF) |
| 206 | Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group | 14.2 | 264 | Citations (PDF) |
| 207 | Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) | 4.3 | 29 | Citations (PDF) |
| 208 | Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data | 14.2 | 1,090 | Citations (PDF) |
| 209 | Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer | 2.7 | 144 | Citations (PDF) |
| 210 | Do All Patients with Metastatic Colorectal Cancer Need Chemotherapy Until Disease Progression? | 2.7 | 7 | Citations (PDF) |
| 211 | Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial | 2.7 | 27 | Citations (PDF) |
| 212 | Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement | 1.7 | 351 | Citations (PDF) |
| 213 | Future Directions in Vascular Endothelial Growth Factor–Targeted Therapy for Metastatic Colorectal Cancer | 2.0 | 13 | Citations (PDF) |
| 214 | Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy? | 5.3 | 1 | Citations (PDF) |
| 215 | IN REPLY | 14.2 | 4 | Citations (PDF) |
| 216 | First- and second-line therapy of metastatic colorectal cancer | 2.7 | 17 | Citations (PDF) |
| 217 | Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy | 2.0 | 55 | Citations (PDF) |
| 218 | Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials | 14.2 | 635 | Citations (PDF) |
| 219 | N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer | 2.7 | 29 | Citations (PDF) |
| 220 | A review of oxaliplatin and its clinical use in colorectal cancer | 2.3 | 99 | Citations (PDF) |
| 221 | Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment | 14.2 | 1,031 | Citations (PDF) |
| 222 | Developments in combination chemotherapy for colorectal cancer | 2.7 | 4 | Citations (PDF) |
| 223 | Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers | 2.7 | 28 | Citations (PDF) |
| 224 | Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer | 2.7 | 15 | Citations (PDF) |
| 225 | Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis | 2.5 | 19 | Citations (PDF) |
| 226 | New chemotherapy approaches in colorectal cancer | 2.3 | 59 | Citations (PDF) |
| 227 | A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats | 2.4 | 12 | Citations (PDF) |
| 228 | Cyclooxygenase-2: a novel target for cancer chemotherapy? | 2.4 | 388 | Citations (PDF) |
| 229 | Cisplatin resistance and oncogenes - a review | 1.5 | 106 | Citations (PDF) |
| 230 | C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines | 6.7 | 108 | Citations (PDF) |
| 231 | Title is missing! | 2.9 | 14 | Citations (PDF) |
| 232 | Diagnostisches und therapeutisches Management der oberen Einflußstauung | 0.2 | 15 | Citations (PDF) |
| 233 | Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin | 1.5 | 3 | Citations (PDF) |
| 234 | Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma | 1.5 | 11 | Citations (PDF) |
| 235 | Metastatic extramammary Paget's disease responding to weekly paclitaxel | 0.4 | 6 | Citations (PDF) |
